Koo ... so right. If allowed to wish, then I wish we had had the knowledge and foresight to include CHF instead of stroke in the primary endpoint. Yeah, then we would likely be at $20+ with a primary end point success, with more and more positive secondary data pouring in for other areas, potentially creating a frenzy of momentum. Really needed that door to open. 

Instead, here we are trying to make sense of some really good data, along with some unexpected data, for the next P3 run, and choice of endpoints.

Coulda/Woulda/Shoulda though ... maybe get a another chance in 2-4 years, and/or perhaps under another name?